London, December 13 – MarketsandMarkets interviewed Karin Jennbacken, Team Leader, Heart Failure in vitro team, AstraZeneca regarding 4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress taking place on 10-11 March 2020 in London – UK. Dr Jennbacken’s team is responsible for target discovery and early development of therapeutics for treatment of patients with cardiovascular disease.
Q. What is the most trending areas of cellular therapies currently?
A. Cardiac therapies using pluripotent stem cells is where most of the researches are going on.
Q. What are the recent developments and technological advancements?
Making universal stem cells is the most promising development in this field currently.
Q. What are the key take away points from your presentation?
A. The attendees would get to know about the key opportunities with PSC derived cardiac cells for patients with heart failure
Q. Hope you had a chance to go through the attached agenda. Please share your feedback on the same, also do let us know which community would be most benefitted by the agenda.
A. I am looking forward to the meeting and explore!
Karin Jennbacken will present on ‘Opportunity and challenges in cardiac cell therapy’ at the event.
The latest conference agenda and complete speaker line-up is available to download on the conference page, where you can also register – https://bit.ly/2qKzuSC
For more inquiries contact Suraj Waghmare, Marketing Executive on email@example.com